Products Investors News Careers Contact SIGA: Human BioArmor MENU Health Security We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security. 1 2 3 OUR PIPELINE OUR TEAM OUR PARTNERS SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Learn More News & Press Releases European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Nov 16, 2021 SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Nov 4, 2021 SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Oct 28, 2021 SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Sep 13, 2021 SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021 Sep 7, 2021 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021 Aug 5, 2021 More News Health Security is a $10 billion market Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases SIGA: Human BioArmor Corporate Headquarters 31 East 62nd Street New York, NY 10065 (212) 672-9100 SIGA Development Operations 4575 SW Research Way, Suite 110 Corvallis, OR 97333 (541) 753-2000 HCP and Product Inquiries: Call 541-766-3744 Privacy Notice © 2021 SIGA Technologies, All Rights Reserved

Skip to main navigation Products Investors News Careers Contact SIGA: Human BioArmor MENU Investor Relations SIGA is concerned about the prevention and treatment of infectious diseases that affect people all over the world. We're very interested in your questions or comments. SIGA has been a publicly traded company since 1997 (SIGA). Stock Information NASDAQ: SIGA $8.87 Change-0.31 (-3.38%) Volume337,042 52 Week High$9.82 52 Week Low$5.66 Nov 24, 2021 4:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Press Releases Nov 16, 2021 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Nov 04, 2021 SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Oct 28, 2021 SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results For Investor Relations questions or requests for literature, please contact Laine Yonker, Edison Group lyonker@edisongroup.com Michael Crawford, Edison Group mcrawford@edisongroup.com Shareholder Tools Print Email Alerts RSS News Feeds Contact IR SIGA: Human BioArmor Corporate Headquarters 31 East 62nd Street New York, NY 10065 (212) 672-9100 SIGA Development Operations 4575 SW Research Way, Suite 110 Corvallis, OR 97333 (541) 753-2000 Privacy Notice © 2021 SIGA Technologies, All Rights Reserved By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies